Key Highlights

  • Revenue was USD 7.78 million against USD 7.04 million estimated; the loss was USD 0.35 per share against USD 0.34.
  • Net product sales were USD 7.8 million, up 30% sequentially, on more than 11,000 filled prescriptions, up 40% sequentially.
  • Gross product Margin was 94%, and the operating loss was USD 6.4 million, an improvement from the second quarter.
  • Cash and cash equivalents were USD 37.8 million, and cash declined only about USD 3.6 million in the quarter.

Alpha Cognition Inc. (NASDAQ:ACOG) reported third quarter 2026 Revenue of USD 7.78 million against an estimate of USD 7.04 million, a beat of about 10.5%. The loss was USD 0.35 per share against an estimate of negative USD 0.34. The company reported after the market close on November 11, 2026, and held its Earnings Call that day.

Management said the third quarter was its strongest since the launch of its Alzheimer's treatment ZUNVEYL, with net product revenues of USD 7.8 million, 30% sequential growth over the second quarter. Net loss for the quarter was USD 7.6 million, or USD 0.35 per share.

Prescriptions and Prescribers

Management said filled prescriptions for the quarter were up 31% from the prior quarter in one measure and that net product sales were driven by over 11,000 filled prescriptions, up 40% sequentially. More than 30,000 prescriptions have been filled across six quarters of commercialization. Net revenue per prescription remained essentially stable at about USD 650 per bottle, which management said shows growth was driven by Volume rather than price.

Management said 2,440 cumulative prescribers had written prescriptions since launch, surpassing its original full year goal of about 2,000, and that it remains on course to exceed its revised goal of 2,500. It said 78% of prescribers placed repeat prescriptions, and productivity rose to approximately seven prescriptions per Writer from approximately six in the second quarter.

Management said that where its reimbursement team supports the prior authorization process, 95% of prescriptions are approved, and 70% of long term care lives have access with a USD 0 copay. It said sequential growth came without a meaningful change in formulary access.

Margins, Costs and Cash

GAAP gross product margin was 94%, consistent with the prior quarter. Other operating expenses were USD 13.7 million against USD 12.9 million in the second quarter and USD 5.6 million in the third quarter of 2025. The operating loss was USD 6.4 million, an improvement from the second quarter that management attributed to revenue growth outpacing spending.

The difference between the operating loss and the net loss reflects approximately USD 1.2 million of nonoperating items, primarily a non-cash charge related to the change in Fair Value of Warrant liabilities. As of September 30, 2026, the company had USD 37.8 million in cash and cash equivalents, with cash declining about USD 3.6 million in the quarter, including approximately USD 1.4 million of proceeds from warrant and stock option exercises.

Items to Follow

Management said its growth and disciplined operating spending align with a goal of achieving operating profitability in 2027. It also said it anticipates additional dataset updates in January and March and anticipates publishing data from a clinical program starting in the first half of 2027. Its partner in Asia continues to work through regulatory processes, with management anticipating approvals in two countries in the near term.

The items to follow are prescription volume, prescriber productivity, operating expenses and the cash balance. The company's legal proceedings and related disclosures are flagged for human legal review.